A 30-day “go-shop” period in St. Jude Medical‘s (NYSE:STJ) pending, $3.4 billion acquisition of Thoratec (NSDQ:THOR) lapsed last week without a 2nd suitor emerging, sending the companies’ stock prices down slightly last Friday. The merger, medtech’s latest multi-billion union, calls for St. Jude to pay $63.50 in cash for each share of Pleasanton, Calif.-based Thoratec, funded using term loans […]
Wall Street Beat
GI Dynamics slashes workforce by 46%
GI Dynamics (ASX:GID) yesterday said it will slash its workforce by 46% by the end of the year, cutting about 25 jobs, after a too-high rate of liver infections forced the halt of a U.S. clinical trial for its EndoBarrier weight loss device. The Lexington, Mass.-based firm said it was making the cuts to cover the cost of […]
Adherium’s $35m Aussie IPO includes $3m from AstraZeneca
Adherium Limited said last week it closed an oversubscribed Australian initial public offering, raising $25.8 million (AU$35 million) with $2.2 million (AU$3 million) coming from pharmaceutical giant AstraZeneca. Adherium is a digital health company that is developing technology targeting suboptimal medication use and remote patient management for chronic disease sufferers, the New Zealand-based company said. […]
Ex-KCI chief Burzik bows out of Palmaz Scientific
Cathy Burzik, the former CEO of Kinetic Concepts Inc., is no longer slated to take the helm at Palmaz Scientific, the company co-founded by coronary stent pioneer Dr. Julio Palmaz in 2008, Palmaz told MassDevice.com today. “We essentially decided not to do the deal because we just didn’t agree,” Palmaz told us in a brief telephone […]
Report: Edwards, Align Technology hackers may dodge insider trading beef
Hackers in a ring that stole confidential information from Edwards Lifesciences (NYSE:EW), Align Technology (NSDQ:ALGN) and others could reportedly dodge insider trading charges because they hacked PR websites rather than the companies they traded in. Although it appears to be a classic insider trading case – the 2 Ukrainian defendants allegedly used confidential information to reap $30 million in trading profits – because the hackers are charged […]
Masimo beats estimates on Q2 prelims
Masimo (NSDQ:MASI) today released preliminary Q2 earnings that are ahead of analysts’ forecasts. Masimo reported preliminary fully-diluted GAAP earnings between 35¢ and 36¢ per share, which is 5¢ to 6¢ ahead of analysts’ expectations on Wall Street. The company reported sales of between $155 million and $156 million, beating even the highest analysts’ forecasts by over $5 […]
Aethlon lists on NASDAQ
Aethlon Medical (OTC:AEMD) said yesterday that the NASDAQ Stock Market has approved its application to begin trading on the Nasdaq Capital Market, beginning July 13. The company’s shares will be traded on the Nasdaq Capital Market under its existing trading symbol AEMD, the San Diego, Calif.-based company said. “Trading on Nasdaq is a pivotal corporate […]
Samsung’s Bioepis considers Nasdaq IPO, seeks funding
(Reuters) – South Korean Samsung‘s (LON:BC94) Bioepis Co Ltd, a developer of generic versions of biotech drugs, said it was considering a Nasdaq IPO – a move that comes as it seeks about $1.3 billion for product development and as the Samsung Group makes a bigger push into biopharmaceuticals. Highlighting growth opportunities for its biopharmaceuticals business may […]
Lantheus prices IPO below range
Lantheus Medical Imaging said yesterday it priced its initial public offering at $6.00 per share, below its previously announced range, for total proceeds of $65 million. The company is offering 10.8 million shares, with an underwriters over-allotment option of another 1.4 million, the North Billerica, Mass.-based company said. Credit Suisse Securities, Jefferies, RBC Capital Markets and […]
IsoRay pledges vigorous defense in shareholder suits
IsoRay (NYSE:ISR) said yesterday that it plans to defend itself from lawsuits filed against it related to a press release published on May 20. The Richland, Wash.-based company is facing putative class-action lawsuits from shareholders accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer. IsoRay […]
IsoRay faces lawsuits alleging fudged clinical data
IsoRay (NYSE:ISR) is facing putative class-action lawsuits from shareholders accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer. The lawsuits, from at least 3 different shareholders, claim that IsoRay made false statements about a clinical study of Cesium 131. The study was the 1st […]